Venture
Ansun Biopharma, Inc.
Latest Form D 2020-11-24- CIK 1534671
- State CA
- Biotechnology
- 7 Form D offerings since 2011-11-10
- Total sold
- $195M
- across 7 offerings
- Rounds
- 7
- Form D offerings since 2011-11-10
- Latest round
- $100M
- 2019-09-09 · 021-348287
- Investors
- 19
- on the latest round
Connected
named in its Form D filingsRound timeline
amount sold · by first filed2019-09-09 · $100M
- 2011-11-10$9.9M021-168528
- 2013-05-29$5M021-197200
- 2014-05-23$7.5M021-217919
- 2015-12-22$4M021-253657
- 2018-03-28$1.7M021-308731
- 2019-08-29$67.1M021-347630
- 2019-09-09$100M021-348287
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($100M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-348287 | First filed2019-09-09 | Latest2020-11-24 | Sought$100M | Sold$100M | Investors19 | Exemptions506(b) |
| 021-347630 | First filed2019-08-29 | Latest2019-08-29 | Sought$67.1M | Sold$67.1M | Investors29 | Exemptions506(b) |
| 021-308731 | First filed2018-03-28 | Latest2018-03-28 | Sought$1.7M | Sold$1.7M | Investors6 | Exemptions506(b) |
| 021-253657 | First filed2015-12-22 | Latest2015-12-22 | Sought$10M | Sold$4M | Investors6 | Exemptions506(b) |
| 021-217919 | First filed2014-05-23 | Latest2014-05-23 | Sought$17.9M | Sold$7.5M | Investors7 | Exemptions506(b) |
| 021-197200 | First filed2013-05-29 | Latest2013-05-29 | Sought$24.3M | Sold$5M | Investors9 | Exemptions506 |
| 021-168528 | First filed2011-11-10 | Latest2011-11-10 | Sought$16M | Sold$9.9M | Investors6 | Exemptions506 |
Who backs Ansun Biopharma, Inc. — 1 inferred investor — and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2020-11-24
| Name | Relationship |
|---|---|
| NANCY CHANG | RelationshipExecutive Officer, Director |
| ALLEN CHAO | RelationshipDirector |
| MICHAEL CHANG | RelationshipDirector |
| Yining Zhao | RelationshipExecutive Officer |
| MICHAEL CHAO | RelationshipDirector |
| DONALD PAYNE | RelationshipDirector |
| AIMIN WU | RelationshipDirector |
| YI SHI | RelationshipDirector |
| DAVE CHENN | RelationshipDirector |
| KAREN LIU | RelationshipDirector |
Sales compensation
Named in Item 12 of its Form D filings
| Recipient | CRD | Broker-dealer | Offerings |
|---|---|---|---|
| China Renaissance Securities (US) Inc. | CRD166318 | Broker-dealer— | Offerings1 |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- California (CA)
- Exemptions
- Rule 506(b); Rule 506
- First filed
- 2011-11-10
- Latest filing
- 2020-11-24
Who backs Ansun Biopharma, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗